Nutrition 21: Adding chromium histidinate to diet improves mood, lessens carb cravings
PURCHASE, N.Y. Nutrition 21 on Thursday reported that the addition of chromium histidinate to one’s diet significantly increased brain serotonin levels, citing recently presented results of a research study before the Experimental Biology 2009 conference in New Orleans that tested its chromium histidinate in animal models of obesity and of diabetes.
Increased serotonin levels are known to improve mood and decrease carbohydrate cravings.
Additional research on chromium was presented by scientists from the U.S.D.A. and from the Medical College of Georgia. The U.S.D.A. study in animals found that chromium histidinate and chromium picolinate reduced the expression of the gene in the brain that produces TAU proteins. The TAU protein is involved in the development of Alzheimer’s disease. Research by MCG demonstrated that high doses of chromium picolinate are safe and does not cause kidney dysfunction in animal models of obesity and of diabetes.
“These results provide a mechanism by which chromium histidinate and chromium picolinate improves mood and reduces carbohydrate cravings,” stated James Komorowski, Nutrition 21 VP technical services and scientific affairs. “The research by the U.S.D.A. provides evidence to support additional research in new chromium applications that address significant quality of life issues in our society. The research by MCG continues to support the safety of chromium picolinate, even at high doses.”
Nutrition 21 owns issued and pending patents on multiple uses of chromium, chromium picolinate and chromium histidinate, the company stated.
“We believe that the research work done by independent organizations like the U.S.D.A. and Medical College of Georgia continues to demonstrate the safety and efficacy of our chromium products in conditions such as obesity and diabetes, and begins to demonstrate the potential to address additional health issues like Alzheimer’s Disease,” commented Michael Zeher, president and CEO of Nutrition 21.
SDI: Rx antivirals drop close to 60%
PLYMOIUTH MEETING, Pa. SDI’s Vector One: National shows that for the week ended May 8, the number of new antiviral prescriptions dispensed at retail pharmacies was 118,578 — a 59% drop compared with approximately 277,000 new prescriptions the week before.
Tamiflu accounted for 90% of the market’s new prescriptions last week, SDI stated Tuesday
PAD patients that use aspirin reduce risk of stroke, study finds
CHICAGO In patients with peripheral artery disease, a blocked leg blood vessel, prophylactic use of aspirin either alone or in conjunction with dipyridamole did not reduce incidence of heart disease, but did reduce the risk of a nonfatal stroke, research published May 13 in the Journal of the American Medical Association has found.
The finding comes from a meta-analysis of studies around aspirin use with PAD.
Overall, studies found a 12% reduction in all cardiovascular events among patients receiving aspirin therapy, compared with those who were not. And while that reduction was considered statistically insignificant, the incidence of nonfatal stroke was 34% lower in the aspirin-taking group.